Clinuvel Pharmaceuticals Limited

CLINUVEL

Pharmaceutical preparations for skin care; Biological and chemical preparations and reagents for medical or veterinary use; and Vaccines; Pharmaceutical preparations and drugs for the treatment of skin disorders; and Diagnostic preparations for medical use;Preparations for tanning the skin for use with sunlight or other ultraviolet light source, namely, suntan lotions and suntan oils; Preparations for tanning the skin without sunlight, namely, self-tanning preparations;

CLINUVEL

Pharmaceuticals and pharmaceutical preparations for the treatment of skin disorders; pharmaceuticals and pharmaceutical preparations for the treatment of skin disorders, based on analogues of melanocyte stimulating hormone, in particular afamelanotide pharmaceuticals and pharmaceutical preparations for the treatment of damaged skin and tissue; pharmaceuticals and pharmaceutical preparations for the treatment of sunburn; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for skin care; medicated skin care preparations; medicated sun tanning preparations; medicated sun tanning preparations for pharmaceutical purposes, based on analogues of melanocyte stimulating hormone, in particular afamelanotide; diagnostic preparations for medical purposes; chemical and biological preparations, substances, reagents and compounds, namely, pharmaceutical preparations for use in dermatology, for skin care, for the treatment of skin disorders, for the protection of the dermis and epidermis, all used in the manufacture, delivery and storage of pharmaceuticals, drugs and diagnostic preparations; vaccines; chemical reagents comprised of polyvalent compounds and synthetic molecules, for medical and veterinary purposes;Non-medicated skin care preparations; non-medicated skin care preparations, namely, cosmetics and cosmetic preparations for skin care, cosmetic preparations for skin care, based on analogues of melanocyte stimulating hormone, in particular afamelanotide, cosmetic nourishing creams, skin cleansing creams, skin lotions for cosmetic purposes, cosmetic sun protecting preparations, cosmetic preparations against sunburn, cosmetic sun protecting lotions, cosmetic sunscreen preparations, cosmetics for tanning the skin including preparations for tanning without sunlight, based on analogues, of melanocyte stimulating hormone, in particular afamelanotide, self-tanning preparations, suntan creams, cosmetic suntan lotions, cosmetic sun milk lotions; non-medicated skin rejuvenation preparations, namely, creams, lotions and cosmetic oils; non-medicated skin rejuvenation products, namely, creams, lotions and cosmetic oils with and without analogues of alpha-melanocyte stimulating hormone; anti-aging skin care preparations, namely, creams, lotions and cosmetic oils; anti-aging moisturizers used as cosmetics, non-medicated anti-aging serum; preparations for tanning the skin including preparations for tanning without sunlight;

SCENESSE

Pharmaceutical preparations, based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, for skin care and for treating skin and skin related conditions and disorders; sun tanning preparations for pharmaceutical purposes, based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide; chemical and biological preparations, substances, reagents and compounds for the delivery and storage of pharmaceuticals which are based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide;Cosmetic preparations for skin care, based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide; sun tanning preparations, cosmetics for tanning the skin including preparations for tanning without sunlight, all based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide;

SCENESSE

Pharmaceutical preparations, based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, for skin care and for treating skin and skin relating conditions and disorders; medicated sun tanning preparations for pharmaceutical purposes, based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide; chemical and biological preparations, substances, reagents and compounds, namely, drug delivery agents consisting of compounds that facilitate the delivery of pharmaceuticals which are based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, and pharmaceutical preparations based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, for use in dermatology, for skin care, for the treatment of skin disorders, for the protection of the dermis and epidermis used in the manufacture, delivery and storage of pharmaceuticals, drugs and diagnostic preparations;Cosmetic preparations for skin care, based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide; non-medicated sun tanning preparations based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide; cosmetics for tanning the skin, namely, cosmetics for tanning the skin based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, and preparations for tanning without sunlight based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide;